文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胰腺神经内分泌肿瘤诊疗一体化的新兴创新技术。

Emerging innovations in theranostics for pancreatic neuroendocrine tumors.

作者信息

Karimi Anita, Bogdani Christina, O'Dwyer Elisabeth, Siolas Despina

机构信息

Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA.

New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York, NY, USA.

出版信息

NPJ Precis Oncol. 2025 May 19;9(1):146. doi: 10.1038/s41698-025-00938-1.

DOI:10.1038/s41698-025-00938-1
PMID:40389624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12089376/
Abstract

Pancreatic neuroendocrine tumors (pNETs) often overexpress somatostatin receptor type 2 (SSTR2), making them ideal targets for theranostics, which integrates molecular imaging with targeted radionuclide therapy. Lu-DOTATATE significantly extends progression-free survival (22.8 vs. 8.5 months) compared to octreotide LAR. Despite these advances, challenges remain, including treatment resistance and long-term toxicities. In this review, we explore advancements in specialized imaging techniques, rationale combination strategies, and exploring next-generation radiopharmaceuticals.

摘要

胰腺神经内分泌肿瘤（pNETs）通常过度表达生长抑素2型受体（SSTR2），这使其成为治疗诊断学的理想靶点，治疗诊断学将分子成像与靶向放射性核素治疗相结合。与奥曲肽长效释放制剂相比，镥[177Lu]奥曲肽显著延长了无进展生存期（22.8个月对8.5个月）。尽管取得了这些进展，但挑战依然存在，包括治疗耐药性和长期毒性。在这篇综述中，我们探讨了专业成像技术的进展、合理的联合策略以及探索下一代放射性药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/12089376/5a9bac7c6aa5/41698_2025_938_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/12089376/0975b427d930/41698_2025_938_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/12089376/5a9bac7c6aa5/41698_2025_938_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/12089376/0975b427d930/41698_2025_938_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b948/12089376/5a9bac7c6aa5/41698_2025_938_Fig2_HTML.jpg

相似文献

[1]
Emerging innovations in theranostics for pancreatic neuroendocrine tumors.

NPJ Precis Oncol. 2025-5-19

[2]
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?

Front Endocrinol (Lausanne). 2022

[3]
[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

Lancet. 2024-6-29

[4]
Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience.

JCO Glob Oncol. 2021-7

[5]
Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.

J Nucl Med. 2023-4

[6]
Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.

Theranostics. 2016-3-10

[7]
177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.

Nucl Med Commun. 2019-12

[8]
Tumor imaging and therapy using radiolabeled somatostatin analogues.

Acc Chem Res. 2009-7-21

[9]
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.

N Engl J Med. 2017-1-12

[10]
Tandem peptide receptor radionuclide therapy using Y/Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience.

Eur J Nucl Med Mol Imaging. 2020-4

引用本文的文献

[1]
Decoding Pancreatic Neuroendocrine Tumors: Molecular Profiles, Biomarkers, and Pathways to Personalized Therapy.

Int J Mol Sci. 2025-8-13

本文引用的文献

[1]
First-in-human study of an optimized, potential kit-type, SSTR antagonist Ga-DATA-LM4 in patients with metastatic neuroendocrine tumors.

Theranostics. 2025-1-20

[2]
Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.

Nucl Med Biol. 2025

[3]
Normal Variants, Pitfalls and Artifacts in Ga-68 DOTATATE PET/CT Imaging.

Front Nucl Med. 2022-2-7

[4]
Survival impact of [Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases.

Eur J Nucl Med Mol Imaging. 2025-1

[5]
[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

Lancet. 2024-6-29

[6]
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with Lu/AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas.

Diagnostics (Basel). 2024-4-26

[7]
Heterogeneous Uptake of 68 Ga-DOTATATE and 18 F-FDG in Initial Diagnosed Neuroendocrine Tumors Patients : Which Patients Are Suitable for Dual-Tracer PET Imaging?

Clin Nucl Med. 2024-6-1

[8]
Head-to-Head Comparison of SSTR Antagonist [Ga]Ga-DATA-LM4 with SSTR Agonist [Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging Study.

Pharmaceuticals (Basel). 2024-2-22

[9]
Charting the Course of Targeted α Therapy With First-in-Human, Postadministration Image-Guided Dosimetry and Response Assessment of 212 Pb-VMT-α-NET in Metastatic Neuroendocrine Tumors.

Clin Nucl Med. 2024-6-1

[10]
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.

EJNMMI Radiopharm Chem. 2024-2-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索